logo
The NYC gunman who killed four left a note to 'study my brain' for CTE. What does that mean?

The NYC gunman who killed four left a note to 'study my brain' for CTE. What does that mean?

The gunman who killed four people inside a New York office this week before turning the gun on himself was carrying a handwritten note that said: "Study my brain."
Shane Tamura wrote that he had chronic traumatic encephalopathy (CTE) — a brain disease diagnosable only after death — investigators said.
But what exactly happened, and what is CTE?
The 27-year-old man from Las Vegas killed four people before taking his own life on the 33rd floor of the Park Avenue skyscraper on Monday.
Officials said he intended to target the NFL headquarters but took the wrong elevator — instead spraying the lobby of a skyscraper and killing four people: a police officer, a security guard and two people who worked at companies in the building.
Police said Tamura had a history of mental illness, and the note found on his body suggested he had a grievance against the NFL over an unsubstantiated claim that he suffered from CTE.
In the three-page note found on his body, the gunman accused the NFL of concealing the dangers of brain injuries linked to contact sports for profits.
In the note, Tamura "claimed to be suffering from CTE, possibly from playing high school football", New York Police Commissioner Tisch said.
"Study my brain. I'm sorry," Tamura was quoted as having written.
The note mentioned a 2013 Frontline documentary featuring former NFL players who suffered from CTE, which has no known treatment and can be caused by repeated shaking of the brain associated with playing contact sports.
Chronic traumatic encephalopathy can affect regions of the brain involved with regulating behaviour and emotions.
This can lead to memory loss, depression, violent mood swings and other cognitive and behavioural issues, though researchers note that these symptoms can also be linked to other illnesses.
Experts say symptoms can arise years or decades after the last brain trauma.
Evidence of the disease has been found not just in those with long professional careers but in high school athletes as well.
We don't know.
CTE can be diagnosed only by examining a brain after death, and it is unclear whether he was showing symptoms.
Tamura was never an NFL player but he did play high school football in California a decade ago and had a history of mental illness, police said without giving details.
The degenerative brain disease has been linked to concussions and other repeated head trauma common in contact sports such as football.
According to Boston University's Chronic Traumatic Encephalopathy Center, progressive degeneration of brain tissue in people with CTE includes the build-up of an abnormal protein called tau in a pattern that distinguishes it from other diseases, such as Alzheimer's.
Researchers have established a connection between CTE and contact sports, military combat and other activities with repeated blows to the head.
After more than a decade of denial, the NFL conceded the link between football and CTE in 2016 testimony before Congress, and has so far paid more than $US1.4 billion ($2.1 billion) to retired players to settle concussion-related claims.
The pioneering efforts of forensic pathologist Bennet Omalu led to the diagnosis of CTE in Pittsburgh Steelers Hall of Fame centre Mike Webster — the first in a former NFL player.
CTE has been diagnosed in more than 100 former NFL players, including NFL Hall of Famers Ken Stabler, Frank Gifford, Junior Seau and most famously Aaron Hernandez, the former New England Patriots star who killed himself in prison at 27 years old while serving a life sentence for a 2013 murder.
Among nearly 2,000 former NFL players, one-third believed they were living with CTE, a 2024 Harvard paper concluded.
During the news conference, Commissioner Tisch said the death of Didarul Islam was "yet another reminder of everything you risk just by showing up to work".
The 36-year-old Bronx officer was the first of four killed in the attack.
He was an immigrant from Bangladesh who served as a police officer in New York City for three and a half years, working in a program that let private companies hire officers for security work.
He was married and had two young boys, and his wife was pregnant with their third child, Commissioner Tisch said.
Blackstone, one of the world's largest investment firms, confirmed one of its employees, Wesley LePatner, was also among those killed.
A Yale graduate, LePatner was a real estate executive, according to Blackstone's website, and she spent more than a decade at Goldman Sachs before joining the firm in 2014.
"She was brilliant, passionate, warm, generous, and deeply respected within our firm and beyond," the firm said in a statement.
A labour union identified the security officer killed as Aland Etienne.
His death "speaks to the sacrifice of security officers" who risked their lives to keep New Yorkers safe, Manny Pastreich, the president of Local 32BJ of the Service Employees International Union, said in a statement.
"Aland Etienne is a New York hero," Pastreich said. "We will remember him as such."
The last victim killed was Julia Hyman, a 2020 graduate of the Cornell Nolan School of Hotel Administration, who was working as an associate at Rudin Management, according to her alma mater.
NFL commissioner Roger Goodell said in a memo to staff that a league employee was seriously injured in the attack and was now stable at a hospital.
He said that "all of our employees are otherwise safe and accounted for".
AP/Reuters/ABC
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Giuffre family demands answers after Trump says Epstein ‘stole' Virginia from Mar-a-Lago
Giuffre family demands answers after Trump says Epstein ‘stole' Virginia from Mar-a-Lago

7NEWS

time13 hours ago

  • 7NEWS

Giuffre family demands answers after Trump says Epstein ‘stole' Virginia from Mar-a-Lago

Donald Trump's admission that Epstein recruited Virginia Giuffre from Mar-a-Lago has sparked outrage from her family, who are now demanding answers about what he knew and when. Speaking aboard Air Force One, the president told reporters that Epstein 'stole' Ms Giuffre from the Mar-a-Lago spa when she was just 16. 'Everyone knows the people who were taken,' Mr Trump said. 'People were taken out of the spa hired by him… And then not too long after that, he did it again. And I said, 'Out of here.'' But the family of Ms Giuffre, who lived in WA before she tragically took her own life, has issued a furious response. 'It was shocking to hear President Trump invoke our sister and say that he was aware that Virginia had been 'stolen' from Mar-a-Lago,' the family said in a statement. 'It makes us ask if he was aware of Jeffrey Epstein and Ghislaine Maxwell's criminal actions, especially given his statement two years later that his good friend Jeffrey 'likes women on the younger side... no doubt about it.'' The comments have sparked renewed scrutiny of Mr Trump's long-denied ties to Epstein and his inner circle, including whether his administration sought to downplay any connection. Mr Trump has previously claimed he 'never had the privilege of going to (Epstein's) island' and insisted Democrats planted his name in case files. But Florida's former attorney general Pam Bondi reportedly told Mr Trump that his name appears 'multiple times' in Epstein-linked documents. Ms Giuffre, who died at the age of 41 in April, was one of the most vocal survivors to speak out about Epstein and Ms Maxwell's trafficking operation. She maintained she was recruited into the ring while working as a locker room attendant at Mar-a-Lago in 2000. Mr Trump officially severed ties with Epstein in 2004. Over the years, he's attributed the falling-out to everything from Epstein being 'a creep' to a dispute over a Palm Beach property. His latest remarks, however, raise new questions about what he knew and when. The Ms Giuffre family also lashed out at Congress over ongoing moves to allow Ms Maxwell to testify about Epstein's network, calling her 'a monster who deserves to rot in prison for the rest of her life.' 'If our sister could speak today, she would be most angered by the fact that the government is listening to a known perjurer,' their statement continued. 'A woman who repeatedly lied under oath and will continue to do so as long as it benefits her position.' Ms Maxwell, currently serving a 20-year sentence, met with Justice Department officials last week. She is scheduled to testify before Congress on August 11, though a request for immunity has already been denied.

Doubling up: How ASX biotechs are multiplying their impact
Doubling up: How ASX biotechs are multiplying their impact

Mercury

time16 hours ago

  • Mercury

Doubling up: How ASX biotechs are multiplying their impact

ASX companies finding smarter ways to stretch value of existing assets and launch into broader clinical areas LTR Pharma leveraging proven intranasal platform for erectile dysfunction treatment to target non-invasive relief for patients with swallowing difficulties From concussion to Alzheimer's the CogState Cognigram digital cognitive assessment system is used by physicians to monitor brain function As global biotech faces increasing pressure to deliver more with less, several ASX-listed healthcare companies are working to find smarter ways to stretch the value of their existing assets. Whether it's repurposing a drug delivery platform, extending the reach of a diagnostic tool or developing next-generation compounds that act on the same biological pathway to treat other conditions, these companies are using proven science as a launchpad into broader clinical territory. The strategy is playing out globally, with Novo Nordisk and Eli Lilly providing high-profile examples of repurposing GLP-1 drugs – originally developed for type 2 diabetes – for weight loss. Blockbusters like Ozempic/Wegovy (Novo Nordisk) and Mounjaro/Zepbound (Eli Lilly) are now reshaping treatment for obesity and related conditions. It's a compelling demonstration of how one well-validated mechanism of action can be leveraged across multiple disease areas in turn lowering development risk, tapping into existing safety and efficacy data, and accelerating time to market. For ASX healthcare companies navigating tighter capital conditions, similar strategies are proving to be a smart and resourceful way to unlock broader clinical value from their existing platforms. LTR Pharma rises above ED with nasal spray tech targeting broader conditions Developer of a nasal spray treatment for erectile dysfunction (ED), LTR Pharma (ASX:LTP) has turned to a secondary program using its innovative intranasal delivery platform but this time for oesophageal motility disorders (OMD). In May, LTR Pharma announced it had inked a collaborative development agreement with US-based Strategic Drug Solutions (SDS) to develop Oroflow a spray for OMD – a group of conditions that cause impaired swallowing (dysphagia). The program leverages LTR's proven proprietary intranasal delivery platform and foundational work from its Spontan and Roxus ED treatments to target rapid symptom relief for patients with swallowing difficulties, potentially offering a non-invasive alternative to current treatments. Oroflow aims to deliver relief in 10 minutes, bypassing swallowing barriers and offering a compelling althernative to treatments including invasive procedures such as pneumatic dilation, surgery, or botulinum toxin injections. LTR Pharma is addressing a $4.5 billion OMD market projected to reach $8.1 bn by 2034 with the company announcing in its latest quarterly report that proof-of-concept testing preparations were underway. LTR Pharma executive chairman Lee Rodne said Oroflow represented an exciting expansion of its nasal spray platform. "For patients with swallowing difficulties, oral medications present obvious challenges for patients," he said. "Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief. Neuren targeting broad set of neurological conditions Neuren Pharmaceuticals (ASX:NEU) is another standout. The company and US partner Acadia was in 2023 granted the first US Food and Drug Administration (FDA) approval for a drug to treat Rett syndrome, a rare neurological disorder mostly affecting girls and emerging in infancy. Trofinetide, marketed as Daybue, is a synthetic analog of part of the hormone insulin-like growth factor 1 (IGF-1), which is a potent regulator of central nervous system development. Neuren is now advancing NNZ-2591, which also targets IGF-1. Building on the scientific foundation of trofinetide, NNZ-2591 is structurally optimised to improve brain penetration, enhance tolerability, and expand therapeutic reach across a broader set of neurodevelopmental conditions. Using a strategy that targets multiple indications from one compound, Neuren aims to accelerate development while reducing R&D expenses. Currently in phase II trials, NNZ-2591 could open new treatment avenues for other underserved neurodevelopmental conditions like Phelan-McDermid, Angelman, and Pitt-Hopkins syndromes. The company is preparing to start a phase III study of NNZ-2591 for its most advanced program Phelin McDermid. It also plans to consult with the FDA this year to establish a clinical path for NNZ-2591 to treat hypoxic-ischemic encephalopathy (HIE), which results from a baby's brain not getting enough oxygen or blood flow before, or shortly after, birth. "We believe the mechanism of action of NNZ-2591 can be broadly applicable to neurodevelopmental disorders, independent of the genetic origin," CEO Jon Pilcher told Stockhead. "We are striving to be successful in multiple settings, for the benefit of both the impacted families and our shareholders." Tracking cognition from concussion to Alzheimer's From footy fields to neurology clinics, the CogState (ASX:CGS) Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of brain function – including processing speed, attention, visual learning, working memory and executive function. The test can assess cognition at a single point in time or track changes over multiple assessments. You may have heard of it referred to as the Cogstate concussion test in footy coverage. However, Cognigram has since evolved into a widely used tool in healthcare and research. Cogstate is riding a wave of global demand for cognition-related clinical trials, particularly in the race to treat Alzheimer's disease and related dementias. The company recently upgraded its financial guidance for FY25, reflecting strong performance and improved outlook across key financial metrics. Full-year profit before tax is forecast to be in the range of $12-14m, an improvement of 69% to 97% on FY24. "We are now using Cognigram, which is the same cognitive assessment used to assess AFL footballers for concussion, to prescreen for clinical trials in the earlier stages of Alzheimer's," CEO Brad O'Connor told Stockhead. "We have a contract with a large pharmaceutical company screening for 20,000 patients in the community to find those that might be appropriate to include in their very early stage Alzheimer's trials. At Stockhead, we tell it like it is. While LTR Pharma is a Stockhead advertiser, the company did not sponsor this article. Originally published as Doubling up: How ASX biotechs are multiplying their impact

Trump's Epstein claim sparks Virginia Giuffre family outrage
Trump's Epstein claim sparks Virginia Giuffre family outrage

Perth Now

time17 hours ago

  • Perth Now

Trump's Epstein claim sparks Virginia Giuffre family outrage

Donald Trump's admission that Epstein recruited Virginia Giuffre from Mar-a-Lago has sparked outrage from her family, who are now demanding answers about what he knew and when. Speaking aboard Air Force One, the president told reporters that Epstein 'stole' Ms Giuffre from the Mar-a-Lago spa when she was just 16. 'Everyone knows the people who were taken,' Mr Trump said. 'People were taken out of the spa hired by him… And then not too long after that, he did it again. And I said, 'Out of here.'' But the family of Ms Giuffre, who lived in WA before she tragically took her own life, has issued a furious response. 'It was shocking to hear President Trump invoke our sister and say that he was aware that Virginia had been 'stolen' from Mar-a-Lago,' the family said in a statement. 'It makes us ask if he was aware of Jeffrey Epstein and Ghislaine Maxwell's criminal actions, especially given his statement two years later that his good friend Jeffrey 'likes women on the younger side... no doubt about it.'' The comments have sparked renewed scrutiny of Mr Trump's long-denied ties to Epstein and his inner circle, including whether his administration sought to downplay any connection. Mr Trump has previously claimed he 'never had the privilege of going to (Epstein's) island' and insisted Democrats planted his name in case files. But Florida's former attorney general Pam Bondi reportedly told Mr Trump that his name appears 'multiple times' in Epstein-linked documents. Ms Giuffre, who died at the age of 41 in April, was one of the most vocal survivors to speak out about Epstein and Ms Maxwell's trafficking operation. She maintained she was recruited into the ring while working as a locker room attendant at Mar-a-Lago in 2000. Mr Trump officially severed ties with Epstein in 2004. Over the years, he's attributed the falling-out to everything from Epstein being 'a creep' to a dispute over a Palm Beach property. His latest remarks, however, raise new questions about what he knew and when. The Ms Giuffre family also lashed out at Congress over ongoing moves to allow Ms Maxwell to testify about Epstein's network, calling her 'a monster who deserves to rot in prison for the rest of her life.' 'If our sister could speak today, she would be most angered by the fact that the government is listening to a known perjurer,' their statement continued. 'A woman who repeatedly lied under oath and will continue to do so as long as it benefits her position.' Ms Maxwell, currently serving a 20-year sentence, met with Justice Department officials last week. She is scheduled to testify before Congress on August 11, though a request for immunity has already been denied.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store